Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

Autor: Paul S. Aisen, Michael W. Weiner, Danielle J Harvey, William J. Jagust, John Q. Trojanowski, Robert C. Green, Alzheimer’s Disease Neuroimaging Initiative, Susan M. Landau, Arthur W. Toga, Leslie M. Shaw, Ronald C. Petersen, Monica Rivera-Mindt, Duygu Tosun, Richard J. Perrin, John C. Morris, Laurel A. Beckett, Andrew J. Saykin, Clifford R. Jack, Ozioma C. Okonkwo, Dallas P. Veitch, Charles DeCarli
Rok vydání: 2021
Předmět:
Oncology
Aging
Epidemiology
Disease
Neurodegenerative
Alzheimer's Disease
tau
screening and diagnosis
biology
Health Policy
AV1541 tau positron emission tomography
amyloid
plasma biomarker
Detection
Psychiatry and Mental health
Neurological
Cohort
Disease Progression
Biomedical Imaging
Alzheimer's Disease Neuroimaging Initiative
medicine.medical_specialty
Amyloid beta
Clinical Sciences
Neuroimaging
tau Proteins
Cellular and Molecular Neuroscience
disease progression
mild cognitive impairment
Developmental Neuroscience
Alzheimer Disease
Internal medicine
mental disorders
Acquired Cognitive Impairment
medicine
Humans
Cognitive Dysfunction
Amyloid beta-Peptides
Vascular disease
business.industry
Prevention
Neurosciences
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
medicine.disease
Brain Disorders
4.1 Discovery and preclinical testing of markers and technologies
Biomarker (cell)
Clinical trial
Geriatrics
biology.protein
Dementia
Neurology (clinical)
Geriatrics and Gerontology
business
Biomarkers
Zdroj: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 18, iss 4
ISSN: 1552-5279
1552-5260
DOI: 10.1002/alz.12422
Popis: INTRODUCTION The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020. METHODS We identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion. RESULTS Disease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity. DISCUSSION ADNI has had a profound impact in improving clinical trials for AD.
Databáze: OpenAIRE
Externí odkaz: